Key facts
- It has raised $175.8M; the latest was Early Stage VC ($36.8M) in Jun 2025.
- Notable investors include Hongshan Capital Group, F-Prime Capital, OrbiMed, Novo Holdings, Catalio Capital Management — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for OnCusp Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for OnCusp Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About OnCusp Therapeutics
Operator of a biopharmaceutical company intended to discover clinically validated treatments for cancer patients worldwide. The company is dedicated to the translation and clinical development of oncology therapeutics, with a focus on bringing preclinical drug candidates to the clinical proof-of-concept stage and then advancing these assets into global early clinical development to quickly establish proof of concept (POC), enabling healthcare companies to commercialize drug candidates in the global market.
- Sector
- Healthcare
- HQ
- Princeton, NJ, United States
- Founded
- 2021
- Employees
- 24
- Website
- oncusptx.com/
- Ownership
- Privately Held (backing)
OnCusp Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in OnCusp Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on OnCusp Therapeutics in its N-PORT filings yet. We sweep new filings monthly.